Literature DB >> 3019586

Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system.

M Packer, W H Lee, P D Kessler.   

Abstract

When renal perfusion pressure is reduced in experimentally induced low-output states, glomerular filtration rate is preserved by angiotensin II-mediated efferent arteriolar vasoconstriction, but available evidence in man suggests that angiotensin II supports renal function only to the extent that it preserves systemic blood pressure. We performed simultaneous assessments of cardiac and renal function in 56 patients with severe chronic heart failure before and after 1 to 3 months of converting-enzyme inhibition. Among the 29 patients with a pretreatment renal perfusion pressure under 70 mm Hg, patients with preserved renal function (creatinine clearance greater than 50 ml/min/1.73 m2) had markedly elevated values for plasma renin activity (11.8 +/- 3.8 ng/ml/hr) and showed a significant decline in creatinine clearance after converting-enzyme inhibition (61.1 +/- 3.0 to 45.9 +/- 5.3 ml/min/1.73 m2; p less than .05). In contrast, although similar with respect to all pretreatment demographic, hemodynamic, and clinical variables, patients with a creatinine clearance under 50 ml/min/1.73 m2 had low values for plasma renin activity (3.4 +/- 0.8 ng/ml/hr) and, despite similar drug-induced decreases in systemic blood pressure, showed no change in creatinine clearance after therapy with captopril or enalapril (32.6 +/- 2.5 to 41.4 +/- 3.8 ml/min/1.73 m2). Changes in creatinine clearance varied linearly and inversely with pretreatment values for plasma renin activity (r = - .64, p less than .001); converting-enzyme inhibition effectively abolished the pretreatment difference in renal function seen in the high- and low-renin subgroups. In the 27 patients with a renal perfusion pressure of 70 mm Hg or greater, creatinine clearance did not vary significantly with plasma renin activity and was not altered by therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019586     DOI: 10.1161/01.cir.74.4.766

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  Low-dose enalapril in severe chronic heart failure.

Authors:  C G Brilla; B Krämer; H M Hoffmeister; W Müller-Schauenburg; T Risler; L Seipel
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

Review 2.  Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.

Authors:  G Hasenfuss; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

3.  Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure.

Authors:  M M McDermott; P Lee; S Mehta; M Gheorghiade
Journal:  Clin Cardiol       Date:  1998-04       Impact factor: 2.882

Review 4.  The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1.

Authors:  Grazia Maria Virzì; Anna Clementi; Alessandra Brocca; Massimo de Cal; Giorgio Vescovo; Antonio Granata; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2014-05-14       Impact factor: 2.041

Review 5.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

6.  A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure.

Authors:  M J Jamieson; J Webster; G Fowler; J Rawles; F W Smith; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 7.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 8.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Comparison of captopril with enalapril in the treatment of heart failure: influence on hemodynamics and measures of renal function.

Authors:  K J Osterziel; R Dietz; K Harder; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

10.  Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention.

Authors:  M D Guazzi; P Agostoni; B Perego; G Lauri; A Salvioni; F Giraldi; M Matturri; M Guazzi; G Marenzi
Journal:  Br Heart J       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.